Kuidas keskusega ühendust võtta
HCP keskus
Alates 1867. aastast on meie haigla pühendunud naiste, laste ja noorukite igakülgsele ravile ning sellest on saanud Euroopa üks olulisemaid spetsialiseerunud pediaatriakeskusi. Meie hooldus põhineb meie spetsialistide multidistsiplinaarsel tööl.
Sant Joan de Déu uurimisfondi kaudu viime läbi uuringuid, et leida uusi ja paremaid ravimeetodeid lastehaigustele.
Ülikooli haiglana panustame koos Barcelona Universitatiga tervishoiutöötajate koolitamisse. Meie eesmärk ei ole mitte ainult edendada ja julgustada meie spetsialistide koolitamist, et parandada meie patsientide ja kogukonna tervist, vaid ka edendada teaduslikke ja inimlikke teadmisi.
Pilt: jordiferrer
Saada sõnum
Hospital Sant Joan de Déu, Spain
meeskond
Dr Marta Morales Ballús
Hispaania
Dr Jaume Català Mora
Hispaania
Dr Itziar Alonso
Hispaania
Dr Isabel Ayet
Hispaania
Dr Elisa Carreras
Hispaania
Dr Ester Casas
Hispaania
Optometrist Ana Díaz
Hispaania
Dr Jesús Díaz
Hispaania
Optometrist Enric Puigventos
Hispaania
Optometrist Carles Fresno
Hispaania
Dr Carmen García Vicuña
Hispaania
Dr Hugo Gonzalez
Hispaania
Optometrist Enrique Jimenez
Hispaania
Dr Ana Llorca
Hispaania
Dr Antonio Federico Martinez Monstseny
Hispaania
Dr Joan Prat
Hispaania
Dr Gemma Romeu
Hispaania
Dr Alicia Serra
Hispaania
Optometrist Simone Suh
Hispaania
Dr Mariona Vidal
Hispaania
Optometrist Begoña Yeste
Hispaania
Dr Núria Planas
Hispaania
Kliinilised uuringud
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation